MCP 201

Drug Profile

MCP 201

Alternative Names: DPI-125

Latest Information Update: 09 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mount Cook Biosciences
  • Developer Mt Cook Pharma
  • Class Analgesics
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 09 Jun 2010 Clinical development is ongoing in USA
  • 29 Dec 2004 Ardent Pharmaceuticals has been acquired by Enhance Biotech
  • 05 Nov 2004 Ardent entered into a feasiblity study, option and license agreement with ALZA Corporation for the development of DPI 125 for the treatment of pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top